Italy's Recordati posts 4.5% 1st-qtr sales growth

8 May 2019

Italian drugmaker Recordati (RECI: MI), which is now 52% owned by private equity fund CVC Capital Partners, has reported that consolidated revenues in the first quarter of 2019 were 383.0 million euros ($428.6 million), up by 4.5% compared to the same period of the preceding year. International sales grow by 4.6%.

Earnings before interest, tax, depreciation and amortization (EBITDA),at 37.6% of sales, were 143.9 million euros, an increase of 7.1% over the first quarter of 2018. Operating income, at 32.9% of sales, was 126.0 million euros, an increase of 4.5% over the same period of the preceding year. Net income, at 24.1% of sales, was 92.1 million euros, an increase of 6.4%.

Recordati’s shares traded up 3.14% to 36.78 euros shortly before market close today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK